Objective-To test whether ETS-related gene (Erg) inhibits tumor necrosis factor (TNF)-␣-dependent endothelial activation and inflammation. Methods and Results-Endothelial activation underlies many vascular diseases, including atherosclerosis. Endothelial activation by proinflammatory cytokines decreases expression of the ETS transcription factor Erg. By using human umbilical vein endothelial cells (HUVECs), we showed that Erg overexpression by adenovirus (AdErg) repressed basal and TNF-␣-induced expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule (VCAM), and interleukin 8 (IL-8). Erg inhibited TNF-␣-dependent activation of the ICAM-1 promoter, nuclear factor (NF)-B activity, and NF-B p65 phosphorylation. Basal NF-B activity was also inhibited by Erg overexpression. Chromatin immunoprecipitation showed that Erg binds to the ICAM-1 proximal promoter region, which contains 7 putative ETS binding sites. To test the anti-inflammatory role of Erg in vivo, we used a murine model of TNF-␣-dependent acute inflammation. The injection of AdErg into the paw decreased TNF-␣-induced inflammation compared with control. Finally, staining of human coronary plaques showed loss of Erg expression from the endothelium overlaying active plaque shoulders. Conclusion-We have identified a novel physiological anti-inflammatory pathway under the control of the transcription factor Erg; this pathway inhibits NF-B-dependent transcription and TNF-␣-induced inflammation in vivo. These results suggest a novel approach to anti-inflammatory therapies. (Arterioscler Thromb Vasc Biol. 2011;31:142-150.) 
M ultiple signaling pathways in endothelial cells (ECs) are activated to modulate gene expression at sites of vascular inflammation. Rapid and transient induction of transcription factors, such as nuclear factor (NF)-B, causes increased expression of target genes, including leukocyte adhesion molecules (eg, intercellular adhesion molecule [ICAM]-1 and vascular cell adhesion molecule [VCAM] ) and the proinflammatory chemokine interleukin (IL) 8. Collectively, these molecules contribute to the recruitment of circulating leukocytes into tissues, a key step in inflammation.
Numerous studies have demonstrated the crucial role of ICAM-1 in leukocyte recruitment and inflammatory diseases. 1 Consequently, the regulation of ICAM-1 gene expression has been extensively investigated. The level of ICAM-1 on quiescent ECs is low and can be upregulated by inflammatory cytokines, including tumor necrosis factor (TNF)-␣, 2 mainly through transcriptional activation of gene expression. Deletion mutant analysis of the 5Ј region upstream from the transcription start site of the human ICAM-1 gene has identified crucial regulatory elements within the first 1.3 kb. [3] [4] [5] Several binding motifs for transcription factors have been identified in this region, including binding sites for NF-B. 6 The NF-B/Rel family of proteins consists of 5 related DNA binding proteins, which combine to form homodimers or heterodimers that bind to a specific DNA consensus sequence. 7 p65:p50 dimers are the most abundant form of NF-B in ECs and are implicated in proinflammatory gene transcription. 8 The proximal NF-B site in the ICAM-1 promoter binds p65 homodimers as well as p65/p50 and p65/c-rel heterodimers and is essential for TNF-␣ induction in ECs. 5, 9, 10 In resting ECs, a small amount of basal NF-B activity is present and drives transcription of constitutive genes, such as ICAM-2 11 and P-selectin. 12 However, in quiescent cells, most NF-B dimers are retained in the cytoplasm in an inactive form by proteins of the inhibitor of B (IB) family. Proinflammatory stimuli, such as TNF-␣, trigger activation of NF-B by inducing IB␣ phosphorylation and degradation, and consequent release of NF-B dimers, which translocate into the nucleus and bind to DNA. 7 The transactivating activity of NF-B in the nucleus involves further posttranslational modifications of NF-B itself, particularly of the p65 subunit. Several studies have shown that phosphorylation of p65 by various stimuli, including TNF-␣, enhances its transcriptional activity. 13 The activity of NF-B is terminated by newly synthesized IB␣, which binds to NF-B and removes it from the nucleus. 14 The ICAM-1 promoter also contains several ETS transcription factor binding sites (EBSs), and ETS factors have been shown in various in vitro cell models to be involved in both activation and repression of ICAM-1 expression. 15, 16 EBSs are found in most endothelial promoters/enhancers described, underlying their importance in endothelial biology. ETS transcription factors share a highly conserved DNA binding domain, the ETS domain, which interacts with DNA at the specific core sequence GGAA/T. ETS factors can act as either activators or repressors of transcription, and this may be dependent on EBS-flanking sequences and/or interacting transcription factors. 17 The most abundantly expressed ETS factor in resting ECs is the ETS-related gene (Erg), which drives the expression of genes that define endothelial lineage, such as endoglin, von Willebrand factor, ICAM-2, and vascular endothelial (VE)-cadherin. 18 Previous studies 19 -21 have shown that Erg is essential for endothelial homeostasis, differentiation, and angiogenesis.
Little is known about the regulation of Erg expression in ECs. Proinflammatory molecules (ie, TNF-␣ and lipopolysaccharides) cause a significant loss in Erg expression in ECs. 11, 22 Recently, Erg was shown to repress constitutive expression of IL-8 in human umbilical vein ECs (HUVECs). 22 We speculated that Erg may exert an antiinflammatory function in ECs by repressing constitutive gene expression and inhibiting cytokine-induced activation; also, its downregulation may be required for proinflammatory signaling.
In this study, we show that Erg interacts with the ICAM-1 promoter and represses constitutive expression of ICAM-1 at the transcription level. We also show that Erg represses TNF-␣dependent activation of NF-B and phosphorylation of p65 serine (Ser) 536 and upregulation of ICAM-1, VCAM, and IL-8. We demonstrate that Erg inhibits acute inflammation in vivo. Finally, we show that Erg is absent from the endothelium above the shoulder regions of atherosclerotic plaques in human coronary arteries. These data show, for the first time, that Erg is an inhibitor of vascular inflammation in vivo.
Methods
The supplemental data (available online at http://atvb.ahajournals.org) provide an expanded Methods section.
Cells
HUVECs were isolated and cultured as previously described. 20 Human coronary artery ECs were grown in endothelial basal medium-2 at 37°C under humidified air (5% CO 2 ) and used between passages 2 and 7.
GeneBloc Transfection and Adenovirus Transduction of HUVECs
To inhibit Erg expression, HUVECs were transfected with antisense oligonucleotides (GeneBloc) as previously described. 20 HUVECs (2.5ϫ10 5 cells per well) were transduced with recombinant adenovirus expressing V5-tagged Erg-3 (AdErg) or ␤-galactosidase (AdLacZ).
Reporter Gene Assays
Reporter gene assays were performed with a commercially available system (Dual-Luciferase Reporter Assay System). The ICAM-1 promoter sequence, containing 1.3 kb upstream of the transcription start site, was isolated from plasmid pBH1.3 and cloned into a vector (pGL4 Luciferase Reporter Vector [pGL4.10], or luc2). The pGL2 NF-B luciferase reporter plasmid was described by Enesa et al. 23 
NF-B DNA Binding Assay
A kit (TransAM Flexi NF-B p65) was used to quantify the binding of the NF-B subunit p65 to the proximal NF-B-responsive element on the ICAM-1 promoter. HUVECs, transduced with AdErg or AdLacZ (multiplicity of infection [MOI]: 50) for 48 hours, were treated with 10-ng/mL human TNF-␣ for 30 minutes and separated into cytoplasmic and nuclear fractions. Nuclear extracts (4 g) were added to a biotinylated 51-bp double-stranded oligonucleotide (ICAM-1 biotin-F and ICAM-1 Reverse, supplemental Table) , corresponding to the ICAM-1 promoter proximal NF-B binding site.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed in HUVECs using ChIP-IT (Active Motif) as previously described. 20 Briefly, sheared chromatin from pooled HUVEC was added to 2 g Erg antibody (sc-353) or negative control rabbit IgG. Immunoprecipitated DNA was then used as a template for real-time PCR, using primers that amplify a region of the ICAM-1 promoter containing the proximal NF-B binding site. Oligonucleotide sequences are given in supplemental Table.
Paw Swelling Model of Acute Inflammation
All experiments used 8-week-old C57BL/6J mice (Harlan Laboratories UK, Blackthorn, London, England). Mice were maintained at the Biological Service Unit, Kennedy Institute of Rheumatology. Studies were performed in accordance with the UK Animals (Scientific Procedures) Act 1986, under Home Office Project License No. 70/5446. Animals (5 mice per group) received a single intraplantar injection of AdErg or AdLacZ (10 7 plaque-forming units). In a separate set of experiments, animals received an intraperitoneal injection of anti-ICAM-1 (100 g) or isotype control antibody. Twenty-four hours later, mice received an intraplantar injection of murine recombinant TNF-␣ (50 ng in 10 L of PBS) or PBS alone (10 L) as control. Paw swelling was measured over 24 hours with microcalipers. At the conclusion of the experiment, paws were dissected postmortem and snap frozen in liquid nitrogen before RNA extraction. RT-PCR was performed using Erg-V5 F and Erg-V5 R primers (supplemental Table) , spanning the region across the Erg-V5 fusion. Comparisons between groups were made using the Student t test. For the paw swelling model, results were analyzed using 2-way ANOVA.
Immunohistochemistry
Human plaques were from a series of paraffin-embedded plaques that derive from autopsy specimens of west of Scotland hospitals. 24 Immunostaining was performed as previously described. 25 Sections were incubated with anti-Erg (sc-353) or anti-von Willebrand factor. Antibody complexes were detected using 3,3-diaminobenzidine tetrahydrochloride and hematoxylin counterstaining. The hind feet of mice were excised after euthanasia and fixed in 10% buffered formalin solution. Fixed specimens were decalcified (Rapid-CalTM) and embedded in paraffin wax. Serial sections were stained with hematoxylin-eosin. Further slides were stained with antibodies to myeloperoxidase, ICAM-1, CD31 (Ab-28364), and Erg (sc-353).
Results

Erg Inhibits Basal ICAM-1 Expression in HUVECs
To establish whether Erg inhibits EC activation, we focused on the ICAM-1 gene. Inhibition of Erg expression in HUVECs, using a well-established antisense approach (Gene-Bloc 19 ) ( Figure 1A and 1B), resulted in a significant increase in ICAM-1 mRNA and total protein levels ( Figure 1C and 1D) and surface expression ( Figure 1E ). Similar results were obtained by inhibiting Erg expression with 2 separate smallinterfering RNA sequences (data not shown). To determine whether Erg represses constitutive ICAM-1 transcription in ECs, we used an ICAM-1 promoter luciferase reporter. Figure 1F shows that inhibition of Erg expression significantly increased ICAM-1 promoter activity in HUVECs compared with control. To confirm that Erg inhibits constitutive ICAM-1 expression in ECs, we used an overexpression strategy and generated an adenovirus encoding for Erg fused to a V5 tag (AdErg). The MOI and optimal time of transduction in HUVECs were determined (supplemental Figure IA and data not shown). An adenoviral vector encoding V5tagged ␤-galactosidase (AdLacZ) was used as control. Figure  2A shows the increase in total Erg mRNA levels in HUVECs transduced with AdErg compared with AdLacZ; expression of both V5-tagged recombinant proteins is shown in Figure  2B . Similar to endogenous Erg, 20 the subcellular localization of exogenous Erg was nuclear (nuclear fractionation experiment, see below). Erg overexpression repressed ICAM-1 mRNA and total protein levels in HUVECs ( Figure 2C and 2D). Similar results were obtained using a lower dose of virus (supplemental Figure ID) . To exclude the possibility that this finding was specific to HUVECs, we repeated the observation using human coronary artery ECs (HCAECs) and found similar results (supplemental Figure IIA and IIB). Erg repression of ICAM-1 basal activity was transcriptional because AdErg repressed ICAM-1 basal promoter activity in a luciferase reporter assay ( Figure 2G , light gray bars) in HUVECs. Therefore, we conclude that Erg acts as a transcriptional repressor of basal ICAM-1 expression in ECs.
Erg Inhibits TNF-␣-Mediated Upregulation of ICAM-1 Expression in HUVECs
TNF-␣ upregulates expression of ICAM-1 while repressing levels of Erg in ECs, 11, 22 suggesting that Erg repression may be required for TNF-␣-mediated proinflammatory activity in ECs. If correct, Erg overexpression would reverse the effects of TNF-␣. To test this hypothesis, we overexpressed Erg in TNF-␣-treated cells. HUVECs transduced with either AdErg or AdLacZ were treated with TNF-␣ for 24 hours. Erg overexpression, confirmed at the mRNA and protein level (supplemental Figure IB To investigate whether Erg inhibits TNF-␣-induced ICAM-1 transcription, HUVECs transduced with AdErg or AdLacZ were transfected with an ICAM-1 promoter luciferase reporter plasmid and subsequently treated with TNF-␣ for 6 hours. As shown in Figure 2G (dark gray bars), TNF-␣-induced ICAM-1 promoter activity was inhibited by Erg overexpression. These results show that Erg inhibits TNF-␣-induced ICAM-1 expression by repressing transcription.
Erg Interacts With the ICAM-1 Promoter
Regulatory regions for both cytokine-independent and cytokine-dependent transcription of the ICAM-1 gene have been mapped within the 206 bp upstream of the transcription start site. 27 Analysis of human and mouse sequences of this region identified 7 conserved putative EBSs ( Figure 3A ), suggesting that Erg may interact with the ICAM-1 promoter. To test this hypothesis, we performed chromatin immunoprecipitation using primers that span the region of the proximal promoter between nucleotides Ϫ188 to Ϫ116 from the transcription start site ( Figure 3A) , which contains a functional TNF-␣responsive NF-B site 5 and 3 putative EBSs, 2 of which are within the NF-B consensus sequence. Figure 3B (left) shows enrichment of the ICAM-1 promoter region by immunoprecipitation with an anti-Erg antibody compared with an isotype control. The amount of total chromatin template, shown as the enrichment in a control region of DNA distal to the promoter, was similar for both Erg and isotype control ( Figure 3B, right) . These results show that Erg binds to the ICAM-1 promoter.
Erg Inhibits Basal and TNF-␣-Induced NF-B Activity in ECs
TNF-␣ upregulation of ICAM-1 can be suppressed by inhibitors of NF-B. 28 To determine whether Erg inhibits the NF-B pathway, HUVECs transduced with AdErg or Ad-LacZ were transfected with an NF-B luciferase reporter plasmid and then treated with TNF-␣ for 6 hours ( Figure 4A , dark gray bars). Erg overexpression significantly inhibited TNF-␣-dependent NF-B-driven reporter activity compared with AdLacZ-transduced cells. Interestingly, Erg overexpression also repressed basal NF-B reporter activity ( Figure 4A , light gray bars). We tested whether Erg inhibited the expression of other NF-B targets and found that Erg overexpression repressed TNF-␣-mediated upregulation of IL-8 and VCAM ( Figure 4B ), 2 important regulators of leukocyte recruitment. These data suggest that Erg has a broad effect as an NF-B inhibitor in ECs. Interestingly, basal expression of IL-8 and VCAM was also decreased after Erg overexpression in HUVECs (supplemental Figure IV) .
NF-B activation is tightly controlled at different levels. In quiescent cells, IBs bind and retain NF-B dimers in the cytoplasm. Degradation of IB␣ releases NF-B, which translocates into the nucleus to bind DNA. 7 To investigate the mechanism through which Erg inhibits NF-B activity, several key steps were tested. Erg overexpression did not affect the rate or extent of IB␣ degradation induced by TNF-␣ in ECs; however IB␣ resynthesis over 2 hours was significantly enhanced in Erg-overexpressing cells ( Figure 4C ). Nuclear translocation of p65:p50 was not affected by Erg overexpression (supplemental Figure VA) , and total levels of p65 and p50 were similar in AdErg-and AdLacZ-transduced cells (supplemental Figure VB) . Moreover, Erg overexpression did not affect TNF-␣-induced p65 binding to the proximal NF-B binding site in the ICAM-1 promoter (Figure 4D) . Thus, the basic steps of IB␣ degradation, nuclear translocation, and DNA binding of NF-B p65 are not affected by Erg; however, Erg appears to regulate the rate and amount of IB␣ resynthesis, suggesting that Erg may promote inhibition of NF-B activation by increasing levels of its inactivating partner.
As previously mentioned, NF-B activity is also regulated by posttranslational modifications. TNF-␣ induces phosphorylation of Ser 536 within the transactivation domain of p65, a modification that affects NF-B transactivating potential. 29, 30 Therefore, we investigated whether Erg modulates p65 phosphorylation at Ser 536 . Basal phosphorylation of Ser 536 in HUVECs was low and confined to the cytoplasm. TNF-␣induced Ser 536 phosphorylation was significantly decreased by Erg overexpression in both the cytoplasm and the nucleus compared with LacZ control cells ( Figure 4E ). Taken together, our data show that Erg represses TNF-␣-induced NF-B activity in ECs through a mechanism that is likely to involve p65 phosphorylation and the turnover of IB␣ resynthesis.
Acute Inflammation: Erg Overexpression Inhibits Inflammation In Vivo
Our data pointed to Erg as a transcriptional repressor of inflammation. Previously, Erg was shown to inhibit leukocyte adhesion to unstimulated HUVECs. 22 To test whether Erg may also repress TNF-␣ induction of leukocyte adhesion, we performed in vitro and in vivo studies. Leukocyte adhesion on TNF-␣-stimulated HUVECs in vitro was studied using a well-characterized assay dependent on multiple factors, including ICAM-1 and IL-8. 31 Labeled human promyelocytic leukemia cells (HL60), which express the ICAM-1 main counterreceptor lymphocyte function-associated antigen-1 (LFA-1), were incubated with HUVECs transduced with AdErg or AdLacZ and activated with TNF-␣. Erg overexpression significantly inhibited HL-60 binding to TNF-␣-activated HUVECs (supplemental Figure VI) , confirming that the inhibition of TNF-␣ signaling by Erg is functionally relevant.
To investigate whether Erg has an anti-inflammatory role in vivo, we used a mouse model of inflammation induced by injection of TNF-␣ in the paw. 32 Inflammation in this model is dependent on ICAM-1 induction because ICAM-1-blocking antibodies significantly suppressed the TNF-␣-induced paw swelling (supplemental Figure VIIA) , whereas PBS injection had no effect on paw swelling (supplemental Figure  VIIB and VIIC) . AdErg or AdLacZ was injected into the mouse footpad 24 hours before TNF-␣ injection in the same area; the resulting paw swelling was measured over time. TNF-␣-induced paw swelling was significantly reduced in mice injected with AdErg compared with control animals ( Figure 5A ), indicating that Erg inhibits acute TNF-␣induced inflammation in vivo. Staining of paw sections near the areas of injection ( Figure 5B ) showed reduced ICAM-1positive vascular structures in AdErg-treated mice compared with control and reduced inflammatory infiltrate (shown by hematoxylin-eosin and myeloperoxidase staining). Expres-sion of exogenous V5-Erg in the footpad of AdErg-injected mice was confirmed by RT-PCR ( Figure 5C ), and immunohistochemistry showed that Erg expression in the paws was prevalently vascular (supplemental Figure VIIIA) . Repression of inflammation was lost with a lower titer of AdErg, suggesting a dose-dependent effect (supplemental Figure  VIIIB) . These results demonstrate that Erg can inhibit TNF-␣-induced acute inflammation in vivo.
Chronic Inflammation: Erg Expression Is Absent in the Endothelium Above the Atherosclerotic Plaque
Monocyte infiltration via endothelial ICAM-1 and VCAM is a key event driving atherosclerosis. 33 Because expression of ICAM-1 and VCAM is upregulated in atherosclerotic lesions, Table) . p65 binding was quantified by ELISA and normalized against AdLacZtransduced cells. E, Cytoplasmic (C) and nuclear (N) fractions from HUVECs transduced with AdLacZ or AdErg and stimulated with TNF-␣ for 30 minutes or left unstimulated were analyzed by Western blot using antibodies to phosphorylated (phospho) p65 (Ser 536 ) and total p65. Values for phospho-p65 are normalized to total p65 and represented as fold change over nuclear fractions from AdLacZ-transduced cells treated with TNF-␣ (nϭ3 to 4). *PϽ0.05 and **PϽ0.01.
we speculated that Erg expression may be decreased at these sites. Analyses of human coronary arteries with eccentric atherosclerotic plaques from 5 different patients ( Figure 6 and supplemental Figure IX) showed that Erg was consistently expressed in nonlesional endothelium ( Figure 6A , i, dotted arrows) but absent from ECs over the shoulder region of the plaque, which actively recruits leukocytes ( Figure 6B , i, dotted arrows). Nuclear and von Willebrand factor staining confirmed the presence of endothelium in both areas ( Figure  6A , ii and 6B, ii, arrows). These results are in line with our data showing that loss of Erg results in increased ICAM-1 expression and leukocyte adhesion.
Discussion
In this article, we demonstrate, for the first time, that the transcription factor Erg inhibits cytokine-driven inflammation and NF-B activity. We show that Erg can repress both basal and TNF-␣-induced expression of ICAM-1, VCAM, and IL-8. We demonstrate the relevance of these findings by showing that Erg represses TNF-␣-induced inflammation in an experimental mouse model. We also find an inverse correlation between Erg expression in the endothelium overlaying human coronary atherosclerotic plaques and the presence of inflammatory infiltration, thus identifying for the first time a potential link between Erg and atherosclerosis.
The ETS transcription factor Erg is found in quiescent and proliferating ECs and plays an important role in endothelial homeostasis and angiogenesis. 18 Erg has been mostly studied as an activator of gene expression. Recently, Yuan et al 22 showed that Erg represses IL-8 expression and inhibits leukocyte adhesion in vitro. Our results support these findings and show that Erg can also repress constitutive endothelial expression of other proinflammatory genes (ie, ICAM-1 and VCAM). Moreover, we demonstrate that Erg inhibits proinflammatory signaling pathways and activation of NF-B. Our results suggest that Erg blocks NF-B activity through multiple mechanisms. We found that Erg overexpression caused increased IB␣ resynthesis over 2 hours after TNF-␣ treatment. IB␣ synthesis is under the control of p65, creating a negative feedback loop: newly synthesized IB␣ binds NF-B in the nucleus and directs the complex back to the cytoplasm, a mechanism that controls the inflammatory response. 34 -36 Thus, it is possible that Erg inhibits NF-B activity partly by increasing quenching by IB␣. Erg overexpression also led to the inhibition of TNF-␣-induced p65 phosphorylation at Ser 536 , a key modification that enhances NF-B transactivation potential, possibly by mediating the association between p65 and CREB-binding protein/p300. 37 Therefore, Erg could reduce the interaction between p65 and CBP/p300 by inhibiting p65 phosphorylation at Ser 536 . A similar mechanism has been described for the antiinflammatory compound tranilast, which inhibits the interaction between NF-B and its transcriptional coactivators. 38 Different kinases have been shown to induce phosphorylation of Ser 536 39 ; Erg may be regulating the expression and/or activity of 1 or more kinases.
Interestingly, the 2 effects of Erg on the NF-B pathway may be linked. Increased IB␣ levels were reported in cells overexpressing a p65 mutant, in which Ser 536 was mutated to alanine, thus preventing phosphorylation; this suggests that this posttranslational modification regulates IB␣ levels. 40 These results raise the possibility that Erg could regulate IB␣ levels by interfering with p65 Ser 536 phosphorylation. Overall, we propose that Erg inhibits NF-B activity in a dual way, by repressing p65 ability to transactivate its target genes and by inducing the expression of the NF-B inhibitor IB␣ after TNF-␣ stimulation. Finally, we cannot rule out that Erg may affect nuclear translocation, DNA binding, and/or posttranslational modifications of other NF-B subunits; however, their role on ICAM-1 transcription appears to be less critical. 5, 9, 10, 41 The mechanism through which Erg inhibits constitutive gene expression is unknown. We show that Erg binds the ICAM-1 promoter directly and inhibits constitutive NF-B activity. Whether the same pathway is responsible for repression of basal and TNF-␣-induced expression of ICAM-1 remains to be determined. NF-B has been implicated in constitutive endothelial expression of genes, including P-selectin 12 and ICAM-2 11 ; preliminary data from our laboratory suggest that NF-B is also involved in basal ICAM-1 expression (A.S., N.H.D., and A.M.R., unpublished data, 2010).
In vivo, AdErg treatment resulted in a significant decrease of inflammation in a TNF-␣-dependent mouse model. These results are encouraging in terms of exploiting Erg's antiinflammatory properties therapeutically. Erg expression was lost from the endothelium overlaying the active shoulders of human coronary plaques, characterized by endothelial activation and macrophage infiltration. This finding, the first associated with human disease, corroborates our in vitro data showing that Erg represses expression of ICAM-1 and VCAM and inhibits leukocyte adhesion. The expression of ICAM-1 and VCAM is increased on the endothelium overlaying inflamed areas of plaque, and both have been impli-cated in the pathogenesis of atherosclerosis. 33 Thus, Erg may have a role in protection from atherosclerosis via regulation of monocyte infiltration.
In conclusion, our results show that Erg can inhibit inflammation in vitro and in vivo and has a broad anti-inflammatory role in ECs by inhibiting NF-Bdependent gene expression and transcription of inflammatory genes. The novelty of these findings resides in the identification of an endogenous protective Erg-dependent pathway in ECs, which could be manipulated pharmacologically for the prevention of inflammatory diseases.
